Generic Bupropion XL Reevaluation Running Behind Schedule
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has received data from just one of four bioequivalence studies of 300 mg bupropion extended-release generics it requested by March from sponsors following Impax/Teva’s withdrawal of their generic version due to lack of bioequivalence.